Drugs Targeting KRAS

• Krazati (adagrasib) – approved for locally advanced or metastatic NSCLC with a G12C change in KRAS as detected by a biomarker test following at least one line of systemic treatment such as chemotherapy.
• Lumakras (sotorasib) – approved for locally advanced or metastatic NSCLC with a G12C change in KRAS as detected by a biomarker test following at least one line of systemic treatment such as chemotherapy.

Learn more about breakthroughs in precision medicine for KRAS mutations.